Alzheimers Disease|OMICS International|Alzheimer's Disease And Parkinsonism

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Levodopa Open Access Journals

Levodopa may be one additional risk factor for BMD loss in PD patients. Bone Mineral Density (BMD) is low in Parkinsons Disease (PD) patients in comparison with age-matched healthy individuals. Bone loss in PD, have some reasons such as immobility, decreased muscle strength and low body weight which leads PD patients to experience osteoporotic symptoms. Basically, carbidopa, which is used in PD to prevent conversion of the levodopa to dopamine, prevents 5-Hydroxytryptophan (5- HTP) metabolism in the liver and causes decreased levels of serotonin in the blood. carbidopa by increasing bone formation rate and compensating BMD loss, which is the main aspect of osteoporosis, in PD patients may lead to reduce osteoporotic symptoms. So the carbidopa should be added to the levodopa to reduce the levodopa side effect on BMD loss in PD patients. The benefits of Open Access journals are apparent enough to raise awareness among scientists and other stakeholders to support for more Open Access Publications from the publishing groups.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on January, 2021